Overview
InhaTarget Therapeutics is a spin-off from the University of Brussels (ULB) dedicated to early development and clinical validation of innovative pulmonary disease treatments via inhalation. The company brings together expertise in drug formulation, inhalation delivery, immunology, preclinical development, and clinical operations, aiming to improve existing molecules through novel treatment modalities.
Leadership & org chart
Alumni
- PRémi RosièreScientific Researcher - entrepreneur→Scientific Advisor at CBX Medical
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.